Actively Recruiting
Corneal Crosslinking for Treatment of Corneal Neovascularization
Led by Price Vision Group · Updated on 2025-07-31
62
Participants Needed
1
Research Sites
280 weeks
Total Duration
On this page
Sponsors
P
Price Vision Group
Lead Sponsor
C
Cornea Research Foundation of America
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
CONDITIONS
Official Title
Corneal Crosslinking for Treatment of Corneal Neovascularization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Active inflammation or infection causing corneal vascularization or melting, or vessels extending into the cornea causing lipid deposits
- Vascularization that may increase risk of rejection for current or planned corneal transplant
- Vessels continuing to extend despite topical corticosteroid treatment
- Signed written informed consent
You will not qualify if you...
- Known sensitivity to treatment medications
- Current condition that may compromise safety or data integrity as judged by the investigator
- Pregnancy, plan to become pregnant, or lactation during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Price Vision Group
Indianapolis, Indiana, United States, 46260
Actively Recruiting
Research Team
M
Marianne Price, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here